| Literature DB >> 10438349 |
S Sei1, S L Sandelli, G Theofan, S Ratto-Kim, M Kumagai, L D Loomis-Price, J H Cox, P Jarosinski, C M Walsek, P Brouwers, D J Venzon, J Xu, P A Pizzo, R B Moss, M L Robb, L V Wood.
Abstract
The safety and preliminary activity of human immunodeficiency virus type 1 (HIV-1) immunogen were evaluated in 10 HIV-1-infected children with disease stage N1,2 or A1,2. Multiple inoculations of 2. 5 or 10 units (U) of HIV-1 immunogen were safe and well tolerated without an acceleration of disease progression. When antiretroviral agents were coadministered, the 10 U dose appeared to be associated with more sustained reduction in plasma HIV-1 RNA than the 2.5 U dose (median log10 HIV-1 RNA at month 18, 3.07 vs. 4.01 copies/mL in 10 U [n=4] vs. 2.5 U [n=3], respectively; P=.034). Levels of regulated-on-activation, normal T cell-expressed and -secreted chemokine produced from HIV-1 immunogen-stimulated lymphocytes in vitro were increased in the children who had HIV-1 immunogen-specific antibody responses (P<.02) and appeared to be inversely correlated with levels of plasma HIV-1 RNA (P<.01). These preliminary data warrant larger studies to determine the effectiveness of adjunctive therapy with HIV-1 immunogen in children with HIV-1 infection.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10438349 DOI： 10.1086/314944
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226